Bioresearch Group Sp. z o.o.

At Bioresearch Group Sp. z o.o. the focus is on cardiovascular diseases, aiming to reduce serious clot‑related complications in high‑risk adults.

• Prevention of atherothrombotic events after acute coronary syndromes or myocardial infarction
• Stroke and systemic embolism prevention in non‑valvular atrial fibrillation
• Treatment and recurrence prevention of deep vein thrombosis and pulmonary embolism

Ongoing studies include bioequivalence assessments of new antiplatelet and anticoagulant formulations, confirming that innovative products match the performance of established therapies and may offer easier dosing or improved safety for patients.

Research at the Warsaw site also targets respiratory tract diseases, seeking better symptom relief for chronic lung patients.

• Maintenance bronchodilator treatment for chronic obstructive pulmonary disease (COPD)
• Comparative evaluation of inhaled drug delivery systems
• Patient‑reported outcome measures in COPD management

The program incorporates bioequivalence studies of inhaled combination products, ensuring that new inhaler formulations provide drug exposure comparable to existing options, ultimately supporting easier and more effective breathing for patients.